Two Year Suspension of Medical Device Tax Signed into Law

Date Posted:
Jan 20, 2016

In a move that has significant positive repercussions for life science companies in the North Bay, the 2.3% medical device tax implemented in 2013 to help fund the Affordable Care Act has been suspended through 2017.

Sara Radcliffe, President and CEO of the statewide California Life Science Association describes the two-year suspension of the tax as a “huge win for patients and medical innovation” going on to note that “we will be working very hard to make sure it’s repealed so that it doesn’t continue to be a burden on innovation.”

Radcliffe’s comments came as part of a Q&A on recent life science policy changes, drug pricing legislation and the coming year in life science policy. To read the full Q&A, please visit the CLSA website.